Now viewpoint
According to England " natural " journal official net reported recently, deep unripe work saves Japan (the main branch of sanitation of responsible medical treatment and social security) the middle ten days of a month gave surgeon of Osaka university heart Ze Fangshu in May (transliteration) the leader's group opened permission to go ahead with some project, approve this group to use revolutionary new-model Cheng technology -- revulsive much abler cell (IPS cell) the clinical research plan that treats heart disease, this is the 2nd of IPS cell clinical application.
First IPS cells treat executive world of next year of research group plan the clinical trial of heart disease. Province of deep unripe work extends " pass " let industry many researcher are excited unceasingly, but the superintendency measure before also a lot of people worry about eye is not adequate still.
IPS cell potential is tremendous
Alleged and revulsive much abler cell, it is the adult cell in organizing the body such as the skin, blood adopt new-model Cheng technique, revulsive into the cell that is similar to embryonic condition, recover differentiation to become the ability of a variety of other type cells thereby.
2006, the person such as cover is extended in the hill that currently holds the post ofdirector of institute of cell of Kyoto university IPS, in using virus carrier to turn the combination of 4 transcribe factor into the body cell of differentiation, the kind of a kind of cell that make its weigh process designing and gets similar embryo does a cell -- IPS cell. Cover is extended to be called accordingly in hill " the father of IPS " , received in glory Nobel 2012 physiological or medical award.
To the second birth medicine such as repair damage organ, IPS cell not less than is a tremendous good news. Although Yinjike is used at making reproductive cell and avoid ethical controversy hard, but photograph of as dry as true human embryo cell is compared, the moral ethics dispute that its face is fewer, get so of many scientists and medical personage chase after hold in both hands, the hope can try to treat disease to suffer from with this technology.
England " natural " journal official net ever sent a message to say on March 28, 2017, a man of Japanese of many years old 60 becomes global first place to accept the person of the retinal cell that produces by other IPS cell. And this, osaka university will use IPS cell to treat heart disease.
The heart that repair is damaged
Before this, ze Fangshu and colleague use IPS cell to make the chip that gave to include cell of 100 million cardiac muscle together. Make clear in the research that has on pig body, these thick the 0.1 millimeter, cell chip that grows 4 centimeters transplants to go up to the heart of the pig, can improve its heart function. Ze Fangshu says, embedded cell is done not have after and heart tissue be in harmony is an organic whole, the main effect of these cardiac muscle cells is to release unripe chief factor, help the cardiac muscle second birth of damage.
It is reported, in newest plan, they will use the IPS cell of the healthy person that offers by Kyoto university to foster cardiac muscle cell, make a diameter a few centimeters, thick the disc form cardiac muscle of about 0.1 millimeter piece, plant this again cardiac muscle piece transplanting arrives on patient heart, in order to improve function of patient cardiac muscle.
The scientist thinks, an advantage of cellular chip is, they can create the cellular matrix that gives their to hold a construction, and the support that does not need to be made with foreign material. Parisian tall treats bitter fleabane skin the production process that Philip Mennasiche participated in surgeon of heart of hospital of Du Ou continent to organize chip, he says: "This is a kind of grace and clever cell is transmissive means. "This is a kind of grace and clever cell is transmissive means..
Wo Fu of pharmacologist of center of medicine of university of German case fourth root pulls Mu - the treatment that introduced from the northern and western nationalities or from abroad Beitusi Cimomanna also is developing a kind to treat heart disease with IPS cell. He says, newest attempt is based on the research that Ze Fangshu and colleague past do 15 years.
Clinical trial of Ze Fangshu will begin at next year, initial stage will have 3 patients to accept treatment, subsequently rejoin 7 people, make whole and clinical trial is added to 10 people. If this one technology is proved safety shows a certain curative effect, so, of domain of medicine of basis Japan second birth " swift passage system " , this one therapeutics will be OK business is used. This makes researcher OK avoid is costly, the extensive clinical trial that aims to prove some therapy curative effect, and the security that will prove therapeutics with small-scale test and effectiveness.
Thoms Yisenhagen of chairman of research center of pharmacologist of German hamburger university, heart and vessels says: "This will cause the attention of the whole world, because a lot of organizations are in forward this direction tries hard. Because a lot of organizations are in forward this direction tries hard..
The expert is anxious to superintend inadequacy
Although academia is valued one piece to clinical trial, but commercialize to its anxiety-ridden however. "Swift passage system " rolled out 2014, aim to accelerate the use of potential lifesaving treatment. Critical personage says, this system is put in blemish, because it allows relevant personnel to be in,did not obtain enough before much data proves treatment is effective, sell its the patient.
In addition, a few researcher are oppugned, whether does the doorsill that approves the treatment that is used at commercial use pass low. Although these cells are safe, but any operations are put in the risk, the therapeutics that because this security and curative effect disable so not certainly, possibly even,the patient meets probably and abandon other remedy. Ethnics home also thinks with superintendency orgnaization, to any new treatment, its benefit must exceed a risk to just have applied value.
You Jingfang of home of cardiology of Japanese Kyoto university is cultivated (transliteration) point out straight from the shoulder, besides satisfying safe requirement, researcher still should prove their therapeutics is effective, this need has a test on more person. He says, evaluate a process to should use the random, clinical trial that can accuse, this is the gold standard that proves medical research is effective. "Although IPS cell therapeutics has very large latent capacity, but contrast as a result of lack experiment, we still cannot determine its whether true get the desired result. The biggest question is, japan lacks sufficient assessment at present system. Japan lacks sufficient assessment at present system..
And spokesman of province of deep unripe work objects however, he is right " natural " the records shows, current approval level is already adequate, because even if has been applied by approval commerce, investigator still needs to provide the evidence with this effective treatment continuously.
To current debate, zefang cultivates self-identity to contrast experiment the importance to proving curative effect. But he also points out, at present he still is in Japan the act below regular frame -- before commercialize, he does not need to contrast group experiment. Province of deep unripe work approves this treatment, it is to admit this therapeutics to have a test on patient body " scientific and reasonable, accord with ethical morality " , as to this therapeutics whether true be successful, "We must find out the answer now " . (reporter Liu Xia)
